JP2017501967A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501967A5 JP2017501967A5 JP2016521985A JP2016521985A JP2017501967A5 JP 2017501967 A5 JP2017501967 A5 JP 2017501967A5 JP 2016521985 A JP2016521985 A JP 2016521985A JP 2016521985 A JP2016521985 A JP 2016521985A JP 2017501967 A5 JP2017501967 A5 JP 2017501967A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- peptide
- xaa
- ala
- arg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 150000001413 amino acids Chemical group 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 238000007385 chemical modification Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000007943 implant Substances 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000011505 plaster Substances 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 238000013268 sustained release Methods 0.000 claims description 4
- 239000012730 sustained-release form Substances 0.000 claims description 4
- 230000008961 swelling Effects 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- DJZAVKNBQZFEAL-QMMMGPOBSA-N (2s)-2-amino-3-(2-aminophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1N DJZAVKNBQZFEAL-QMMMGPOBSA-N 0.000 claims description 2
- NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 2
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 229960002173 citrulline Drugs 0.000 claims description 2
- 235000013477 citrulline Nutrition 0.000 claims description 2
- 229960003104 ornithine Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 description 6
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361890056P | 2013-10-11 | 2013-10-11 | |
| US61/890,056 | 2013-10-11 | ||
| US201461940095P | 2014-02-14 | 2014-02-14 | |
| US61/940,095 | 2014-02-14 | ||
| PCT/US2014/058646 WO2015054006A2 (en) | 2013-10-11 | 2014-10-01 | Novel peptide compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017501967A JP2017501967A (ja) | 2017-01-19 |
| JP2017501967A5 true JP2017501967A5 (https=) | 2017-11-09 |
Family
ID=52813728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521985A Pending JP2017501967A (ja) | 2013-10-11 | 2014-10-01 | 新規なペプチド組成物 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3054967A4 (https=) |
| JP (1) | JP2017501967A (https=) |
| KR (1) | KR20160065969A (https=) |
| CN (1) | CN105828831A (https=) |
| AU (1) | AU2014332346B2 (https=) |
| BR (1) | BR112016007816A2 (https=) |
| CA (1) | CA2926641A1 (https=) |
| CL (1) | CL2016000836A1 (https=) |
| IL (1) | IL244956B (https=) |
| MX (1) | MX2016004660A (https=) |
| RU (1) | RU2016112931A (https=) |
| SG (1) | SG11201602661PA (https=) |
| WO (1) | WO2015054006A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017150327A1 (ja) * | 2016-03-03 | 2017-09-08 | 不二製油グループ本社株式会社 | 神経栄養因子の脳内分泌促進するための食品添加用組成物 |
| WO2018151352A1 (ko) * | 2017-02-16 | 2018-08-23 | (주)케어젠 | 살리실산과 펩타이드의 결합체 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4244946A (en) | 1979-06-11 | 1981-01-13 | The Salk Institute For Biological Studies | Water-soluble peptides affecting gonadal function |
| US4305872A (en) | 1979-10-19 | 1981-12-15 | Kenneth Wingrove | Polypeptide derivatives |
| US4316891A (en) | 1980-06-14 | 1982-02-23 | The Salk Institute For Biological Studies | Extended N-terminal somatostatin |
| US6031072A (en) | 1996-07-12 | 2000-02-29 | Mcgill University | Compounds and methods for modulating cell adhesion |
| US20020168761A1 (en) | 2000-01-24 | 2002-11-14 | Gour Barbara J. | Peptidomimetic modulators of cell adhesion |
| EP1572887A4 (en) * | 2001-08-24 | 2008-12-24 | Neuren Pharmaceuticals Ltd | NERVE REGENERATING PEPTIDE AND METHOD FOR THEIR USE IN THE TREATMENT OF A BRAIN DAMAGE |
| US7563862B2 (en) | 2001-08-24 | 2009-07-21 | Neuren Pharmaceuticals Limited | Neural regeneration peptides and methods for their use in treatment of brain damage |
| WO2004058807A2 (en) * | 2002-12-24 | 2004-07-15 | Algonomics N.V. | Mhc class i restricted t-cell stimulating peptides from hepatitis b virus |
| JP5026083B2 (ja) * | 2003-10-31 | 2012-09-12 | クロンズ ホールディングズ カンパニー リミテッド | 神経再生ペプチド及び脳損傷治療におけるそれらの使用方法 |
| WO2007011595A2 (en) * | 2005-07-15 | 2007-01-25 | Neuren Pharmaceuticals Limited | Neural regeneration peptides and antioxidants protect neurons from degeneration |
| JP2013532172A (ja) * | 2010-07-09 | 2013-08-15 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | 安定化したインスリン分泌促進ペプチド及び使用方法 |
| KR20140140546A (ko) * | 2012-02-10 | 2014-12-09 | 타릭스 파마슈티컬스 엘티디. | 말초 혈관 질환의 치료를 위한 조성물 및 방법 |
-
2014
- 2014-10-01 AU AU2014332346A patent/AU2014332346B2/en not_active Ceased
- 2014-10-01 BR BR112016007816A patent/BR112016007816A2/pt not_active Application Discontinuation
- 2014-10-01 EP EP14852391.3A patent/EP3054967A4/en not_active Withdrawn
- 2014-10-01 RU RU2016112931A patent/RU2016112931A/ru not_active Application Discontinuation
- 2014-10-01 JP JP2016521985A patent/JP2017501967A/ja active Pending
- 2014-10-01 KR KR1020167011913A patent/KR20160065969A/ko not_active Withdrawn
- 2014-10-01 SG SG11201602661PA patent/SG11201602661PA/en unknown
- 2014-10-01 CA CA2926641A patent/CA2926641A1/en not_active Abandoned
- 2014-10-01 WO PCT/US2014/058646 patent/WO2015054006A2/en not_active Ceased
- 2014-10-01 MX MX2016004660A patent/MX2016004660A/es unknown
- 2014-10-01 CN CN201480066852.9A patent/CN105828831A/zh active Pending
-
2016
- 2016-04-06 IL IL24495616A patent/IL244956B/en not_active IP Right Cessation
- 2016-04-11 CL CL2016000836A patent/CL2016000836A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8580918B2 (en) | Peptidic GLP-2 agonists | |
| EP2427475B1 (en) | High penetration prodrug compositions of peptides and peptide-related compounds | |
| JP2021046436A (ja) | ペプチド模倣大環状分子およびその製剤 | |
| JP2011518179A5 (https=) | ||
| CN101983205B (zh) | 催产素类似物 | |
| JP2012500001A5 (https=) | ||
| CA2489227A1 (en) | Hla-a24-restricted cancer antigen peptides | |
| HUP0003592A2 (hu) | LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények | |
| JPS5962556A (ja) | 非天然アミノ酸 | |
| AR066648A1 (es) | Peptido ciclizado por lactamas, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de canceres artritis reumatica, fibrosis pulmonar e infeccion por vih | |
| JP2019533722A5 (https=) | ||
| JP2008521840A5 (https=) | ||
| CN116802189A (zh) | 制备肽的方法 | |
| JP2012524775A5 (https=) | ||
| IL105795A (en) | Cyclopeptides and pharmaceutical compositions containing them for promoting absorption when applied to the mucosa | |
| JP6721419B2 (ja) | エズリン由来ペプチド、およびその医薬組成物 | |
| JP2017501967A5 (https=) | ||
| JP2013542196A5 (https=) | ||
| RU2016112931A (ru) | Композиции новых пептидов | |
| JP2001514659A (ja) | ドラスタチン−１５誘導体とタキサンとの併用 | |
| JP2008531463A5 (https=) | ||
| JP5477794B2 (ja) | エンドキニンｃ／ｄ由来のペプチド | |
| AU671118B2 (en) | Tachykinin antagonist tricyclic compounds, preparation of same and pharmaceutical compositions containing such compounds | |
| US10131692B2 (en) | Vasopressin-2 receptor agonists | |
| CN107955061B (zh) | 地加瑞克关键中间体的制备方法 |